Hospital
Prime Healthcare Services-Port Huron LLC
Prime Healthcare Services-Port Huron LLC was paid $15.15M by Medicaid between Jan 2018 and Dec 2024, across 245 billing codes. Its largest line is 99285, emergency room visit (most serious) — 23% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES-PORT HURON LLC
PORT HURON, MI 48060
PORT HURON, MI 48060
33aNPI1306227764assigned 06/11/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.15M
24GClaims574,617
24DCodes billed245
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#54 of 86
Median peer was paid$21.55M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,013 | $1.71M | |
| 2019 | 80,307 | $2.00M | |
| 2020 | 64,423 | $1.61M | |
| 2021 | 78,818 | $2.18M | |
| 2022 | 104,390 | $2.70M | |
| 2023 | 108,906 | $2.68M | |
| 2024incomplete | 84,760 | $2.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 11,483 | 10,752 | $3.48M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 17,160 | 16,301 | $3.21M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 20,649 | 19,589 | $2.57M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.0% | 9,713 | 9,025 | $902K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 2,349 | 2,239 | $336K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 5,764 | 5,505 | $274K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 8,023 | 7,376 | $238K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 2,910 | 2,800 | $232K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 7,180 | 6,497 | $231K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 2,217 | 2,158 | $226K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 5,979 | 5,685 | $215K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 9,723 | 2,600 | $208K |
233 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 2,125 | $204K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 5,620 | $169K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 4,457 | $167K |
| 80061 | Lipid panel | 1.1% | 10,229 | $162K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 1,895 | $159K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 9,262 | $159K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,807 | $147K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,130 | $125K |
| G0378 | Hospital observation service, per hour | <1% | 959 | $107K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,215 | $107K |
| 80053 | Comprehensive metabolic panel | <1% | 28,163 | $99K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,259 | $96K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,796 | $82K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,929 | $63K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,263 | $61K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 883 | $52K |
| 84439 | <1% | 9,399 | $47K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,029 | $43K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,677 | $43K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,584 | $41K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 861 | $34K |
| 88142 | <1% | 2,698 | $28K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,130 | $27K |
| 86003 | <1% | 498 | $26K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 69 | $26K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,320 | $24K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,799 | $24K |
| 82607 | <1% | 2,744 | $23K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,213 | $22K |
| 83970 | <1% | 882 | $21K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,196 | $21K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,119 | $21K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 26 | $19K |
| 87081 | <1% | 6,127 | $19K | |
| 82728 | <1% | 2,332 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,628 | $18K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,498 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,507 | $15K |
| 97162 | <1% | 281 | $14K | |
| 88342 | <1% | 727 | $14K | |
| 74018 | <1% | 583 | $13K | |
| 82947 | <1% | 586 | $13K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 50 | $12K |
| 83550 | <1% | 2,356 | $12K | |
| 83735 | <1% | 5,087 | $12K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 25 | $11K |
| 73610 | <1% | 1,353 | $11K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 130 | $11K |
| 73630 | <1% | 1,615 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 27,885 | $10K |
| 76536 | <1% | 184 | $10K | |
| 83540 | <1% | 2,486 | $9K | |
| 86140 | <1% | 3,873 | $9K | |
| 85027 | <1% | 3,494 | $9K | |
| 86803 | <1% | 1,021 | $9K | |
| 84153 | <1% | 791 | $8K | |
| 72100 | <1% | 345 | $8K | |
| 87186 | <1% | 3,192 | $8K | |
| 85651 | <1% | 3,854 | $8K | |
| 87420 | <1% | 1,708 | $8K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 74 | $8K |
| 87070 | <1% | 1,963 | $8K | |
| 84460 | <1% | 2,414 | $7K | |
| 73130 | <1% | 1,439 | $7K | |
| 84450 | <1% | 2,383 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 77 | $7K |
| 73562 | <1% | 1,009 | $7K | |
| 73030 | <1% | 660 | $7K | |
| 94762 | <1% | 303 | $6K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 111 | $6K |
| 81001 | <1% | 11,887 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 569 | $6K |
| 76830 | Ultrasound, transvaginal | <1% | 102 | $6K |
| 84481 | <1% | 642 | $6K | |
| 87077 | <1% | 2,034 | $6K | |
| 84550 | <1% | 2,246 | $6K | |
| 82570 | <1% | 1,875 | $6K | |
| 82043 | <1% | 1,655 | $6K | |
| 82550 | <1% | 3,564 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,271 | $5K |
| 84403 | <1% | 318 | $5K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,456 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,474 | $5K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $5K |
| 87340 | <1% | 782 | $5K | |
| 76770 | <1% | 79 | $4K | |
| 73110 | <1% | 622 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 210 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 83 | $4K |
| 80074 | <1% | 157 | $4K | |
| 72131 | <1% | 64 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,427 | $3K |
| 80076 | <1% | 1,740 | $3K | |
| 97035 | <1% | 590 | $3K | |
| 84702 | <1% | 796 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $3K |
| 97116 | <1% | 204 | $3K | |
| 83880 | <1% | 1,395 | $3K | |
| 85613 | <1% | 474 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,642 | $3K |
| 82746 | <1% | 311 | $3K | |
| 83001 | <1% | 210 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 268 | $2K |
| 10060 | <1% | 26 | $2K | |
| 83690 | <1% | 9,214 | $2K | |
| 93971 | <1% | 42 | $2K | |
| 84100 | <1% | 858 | $2K | |
| 85610 | <1% | 6,209 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 25 | $2K |
| 76801 | <1% | 27 | $2K | |
| 82565 | <1% | 703 | $2K | |
| 86038 | <1% | 238 | $2K | |
| 82785 | <1% | 177 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 16 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 58 | $2K |
| 86160 | <1% | 208 | $1K | |
| 82784 | <1% | 155 | $1K | |
| 73502 | <1% | 115 | $1K | |
| 85007 | <1% | 1,112 | $1K | |
| 74019 | <1% | 177 | $1K | |
| 85730 | <1% | 5,606 | $1K | |
| 84520 | <1% | 575 | $1K | |
| 87486 | <1% | 50 | $1K | |
| 87581 | <1% | 50 | $1K | |
| 29515 | <1% | 13 | $1K | |
| 81003 | <1% | 4,908 | $992.13 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $946.00 |
| 84484 | <1% | 5,444 | $936.84 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 76 | $884.45 |
| 81025 | <1% | 7,823 | $832.35 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 16 | $831.86 |
| 0012A | <1% | 27 | $821.79 | |
| 76641 | <1% | 14 | $775.32 | |
| 82248 | <1% | 244 | $745.64 | |
| 86900 | <1% | 537 | $722.41 | |
| 71250 | <1% | 13 | $720.84 | |
| 86376 | <1% | 99 | $715.34 | |
| 84144 | <1% | 58 | $699.52 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,985 | $689.33 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 56 | $658.45 |
| 83002 | <1% | 58 | $632.45 | |
| 84156 | <1% | 273 | $536.17 | |
| 80164 | <1% | 84 | $535.30 | |
| 0011A | <1% | 31 | $516.35 | |
| 80178 | <1% | 140 | $488.81 | |
| 86769 | <1% | 14 | $485.86 | |
| 85379 | <1% | 1,173 | $376.46 | |
| 86800 | <1% | 39 | $334.03 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 27 | $327.05 |
| 83605 | <1% | 3,431 | $277.01 | |
| 73090 | <1% | 78 | $274.44 | |
| 87040 | <1% | 2,989 | $260.57 | |
| 74022 | <1% | 341 | $249.38 | |
| 86665 | <1% | 23 | $239.65 | |
| 72110 | <1% | 12 | $238.56 | |
| 84402 | <1% | 13 | $218.66 | |
| 70486 | <1% | 14 | $178.92 | |
| 86364 | <1% | 18 | $167.40 | |
| 82962 | <1% | 3,223 | $153.09 | |
| 82533 | <1% | 16 | $144.38 | |
| 87205 | <1% | 88 | $141.54 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 553 | $138.66 |
| 84146 | <1% | 13 | $136.04 | |
| 82150 | <1% | 128 | $129.69 | |
| 82247 | <1% | 40 | $119.55 | |
| 86850 | <1% | 333 | $97.68 | |
| 73590 | <1% | 30 | $96.66 | |
| 86231 | <1% | 12 | $91.66 | |
| 88304 | <1% | 14 | $58.41 | |
| 71101 | <1% | 13 | $57.30 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,230 | $40.56 |
| 86901 | <1% | 537 | $38.66 | |
| 86431 | <1% | 12 | $27.80 | |
| 84145 | <1% | 263 | $17.93 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,192 | $3.85 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 313 | $3.56 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,212 | $3.17 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,015 | $2.28 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,644 | $1.13 |
| J3490 | Unclassified drugs | <1% | 7,594 | $0.90 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,052 | $0.36 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,605 | $0.25 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,190 | $0.22 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 2,105 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 86 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 871 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 175 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 770 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 25 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 329 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 73 | $0.00 |
| 29125 | 0% | 107 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 49 | $0.00 |
| 90715 | 0% | 214 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 96 | $0.00 |
| 12011 | 0% | 12 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 27 | $0.00 |
| A4223 | Infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately) | 0% | 76 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 16 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 59 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 73 | $0.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 20 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 4,050 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,212 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 740 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 3,754 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 893 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 364 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,488 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,204 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 203 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 267 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 245 | $0.00 |
| 96376 | 0% | 885 | $0.00 | |
| 94760 | 0% | 307 | $0.00 | |
| A4615 | Cannula, nasal | 0% | 12 | $0.00 |
| 80320 | 0% | 219 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 15 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 25 | $0.00 |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 101 | $0.00 |
| 87808 | 0% | 32 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 157 | $0.00 |
| 12001 | 0% | 202 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 23 | $0.00 |
| 91301 | 0% | 60 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 27 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 101 | $0.00 |
| 87807 | 0% | 12 | $0.00 | |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | 0% | 13 | $0.00 |
| A4215 | Needle, sterile, any size, each | 0% | 12 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, REBEKAH (PRESIDENT AND CEO)